Targeted cardiometabolic therapeutics for diabetes and related metabolic conditions
Sparrow Pharmaceuticals, Inc. is dedicated to delivering improved outcomes for patients managing diabetes and related metabolic conditions through targeted cardiometabolic therapeutics. Located at 920 SW 6th Ave, Suite 1200, Portland, Oregon 97204, US, Sparrow Pharmaceuticals is focused on developing innovative solutions to address the underlying causes of treatment resistance in metabolic dysfunction.
With its lead candidate, clofutriben, a first-in-class, once-daily, oral HSD-1 inhibitor, Sparrow Pharmaceuticals is initially targeting type 2 diabetes with elevated cortisol. Sparrow Pharmaceuticals aims to complement existing antidiabetic agents and enhance treatment efficacy. The company leverages precision medicine to create impactful therapies.
Sparrow Pharmaceuticals continues to advance its research and development efforts, solidifying its position as a key player in the pharmaceutical industry. We invite the manager of Sparrow Pharmaceuticals to create a customized and exclusive company showcase and product listing on our platform to further amplify your reach and connect with potential partners and clients.
Sparrow Pharmaceuticals, Inc. se consacre à améliorer les résultats pour les patients gérant le diabète et les conditions métaboliques connexes grâce à des thérapies cardiométaboliques ciblées. Située au 920 SW 6th Ave, Suite 1200, Portland, Oregon 97204, États-Unis, Sparrow Pharmaceuticals se concentre sur le développement de solutions innovantes pour traiter les causes sous-jacentes de la résistance au traitement dans les dysfonctionnements métaboliques.
Avec son principal candidat, le clofutriben, un inhibiteur oral HSD-1 unique en son genre, administré une fois par jour, Sparrow Pharmaceuticals cible initialement le diabète de type 2 avec un cortisol élevé. Sparrow Pharmaceuticals vise à compléter les agents antidiabétiques existants et à améliorer l'efficacité du traitement. L'entreprise exploite la médecine de précision pour créer des thérapies percutantes.
Sparrow Pharmaceuticals continue de faire progresser ses efforts de recherche et développement, consolidant ainsi sa position d'acteur clé dans l'industrie pharmaceutique. Nous invitons le responsable de Sparrow Pharmaceuticals à créer une vitrine d'entreprise et une liste de produits personnalisées et exclusives sur notre plateforme afin d'amplifier davantage votre portée et de vous connecter avec des partenaires et des clients potentiels.
Compare Sparrow Pharmaceuticals, Inc. with 3 companies in Pharmaceutical-Manufacturing
| Comparison Field |
Sparrow Pharmaceuticals,...Main Company |
Tr
TransCelerate BioPha...View Profile |
Phathom Pharmaceutic...View Profile |
Mobius MedicalView Profile |
|---|---|---|---|---|
|
Founded Year
|
— | 2012 | 2018 | 2008 |
|
Company Size
|
— | 11-50 | 201-500 | 51-200 |
|
City
|
Portland, Oregon | Conshohocken, Pennsylvania | Florham Park, New Jersey | North Sydney, New South Wales |
|
Country
|
United States | United States | United States | Australia |
|
Skills & Keywords
Comparing with main company
|
16 Total Skills
Pharmaceuticals
Cardiometabolic Therapeutics
Diabetes Treatment
Metabolic Conditions
HSD-1 Inhibitor
Precision Medicine
Drug Development
Giant cell arteritis
Drug development
Autoimmune diseases
New chemical entity
Cushing's syndrome
Clinical trials
Corticosteroids
Inflammatory diseases
Polymyalgia rheumatica
|
5 Total
5 Unique
Unique Skills:
Clinical data transparency
Clinical trial operations
Research & development
Risk based monitoring
Site qualification & training
|
6 Total
6 Unique
Unique Skills:
Biotechnology
Commercialization
Gastrointestinal
GI
Innovation
R&D
|
8 Total
8 Unique
Unique Skills:
Australia clinical trials
Contract Research Organization
CRO
EDC
Medical devices
New Zealclinical trials
+2
|
Other organizations in the same industry
This company is also known as